Transcatheter Aortic Valve Replacement in Patients With Severe Mitral or Tricuspid Regurgitation at Extreme Risk for Surgery

Patients with symptomatic severe aortic stenosis and severe mitral regurgitation (SMR) or severe tricuspid regurgitation (STR) were excluded from the major transcatheter aortic valve replacement (TAVR) trials. We studied these 2 subgroups in patients at extreme risk for surgery in the prospective, non-randomized, single-arm CoreValve US Expanded Use Study.

Source: The Journal of Thoracic and Cardiovascular Surgery - January 21, 2018 Category: Cardiovascular & Thoracic Surgery Authors: Stephen H. Little, Jeffrey J. Popma, Neal S. Kleiman, G. Michael Deeb, Thomas G. Gleason, Steven J. Yakubov, Stan Checuti, Daniel O ’Hair, Tanvir Bajwa, Mubashir Mumtaz, Brijeshwar Maini, Alan Hartman, Stanley Katz, Newell Robinson, George Petrossian, J Source Type: research